[HTML][HTML] The synaptic hypothesis of schizophrenia version III: a master mechanism

OD Howes, EC Onwordi - Molecular Psychiatry, 2023 - nature.com
The synaptic hypothesis of schizophrenia has been highly influential. However, new
approaches mean there has been a step-change in the evidence available, and some tenets …

[HTML][HTML] Towards a youth mental health paradigm: a perspective and roadmap

PJ Uhlhaas, CG Davey, UM Mehta, J Shah… - Molecular …, 2023 - nature.com
Most mental disorders have a typical onset between 12 and 25 years of age, highlighting the
importance of this period for the pathogenesis, diagnosis, and treatment of mental ill-health …

New and emerging treatments for schizophrenia: a narrative review of their pharmacology, efficacy and side effect profile relative to established antipsychotics

MC Lobo, TS Whitehurst, SJ Kaar, OD Howes - … & Biobehavioral Reviews, 2022 - Elsevier
Schizophrenia is associated with substantial unmet needs, highlighting the necessity for
new treatments. This narrative review compares the pharmacology, clinical trial data and …

[HTML][HTML] Controversies surrounding the use of long-acting injectable antipsychotic medications for the treatment of patients with schizophrenia

JM Kane, JP McEvoy, CU Correll, PM Llorca - CNS drugs, 2021 - Springer
Schizophrenia is a serious mental illness that requires continuous and effective long-term
management to reduce symptoms, improve quality of life, and prevent relapse. Oral …

[HTML][HTML] Prognostic accuracy and clinical utility of psychometric instruments for individuals at clinical high-risk of psychosis: a systematic review and meta-analysis

D Oliver, M Arribas, J Radua, G Salazar de Pablo… - Molecular …, 2022 - nature.com
Accurate prognostication of individuals at clinical high-risk for psychosis (CHR-P) is an
essential initial step for effective primary indicated prevention. We aimed to summarise the …

[HTML][HTML] Neurophysiology in psychosis: The quest for disease biomarkers

B Wang, E Zartaloudi, JF Linden, E Bramon - Translational Psychiatry, 2022 - nature.com
Psychotic disorders affect 3% of the population at some stage in life, are a leading cause of
disability, and impose a great economic burden on society. Major breakthroughs in the …

Reducing the duration of untreated psychosis (DUP) in a US community: a quasi-experimental trial

VH Srihari, M Ferrara, F Li, E Kline… - Schizophrenia …, 2022 - academic.oup.com
Abstract Objective Duration of Untreated Psychosis (DUP) remains unacceptably long and
limits effectiveness of care. To determine whether an early detection campaign (“Mindmap”) …

[HTML][HTML] MicroRNAs in the Onset of Schizophrenia

KT Thomas, SS Zakharenko - Cells, 2021 - mdpi.com
Mounting evidence implicates microRNAs (miRNAs) in the pathology of schizophrenia.
These small noncoding RNAs bind to mRNAs containing complementary sequences and …

Employment and relationship outcomes in first-episode psychosis: a systematic review and meta-analysis of longitudinal studies

O Ajnakina, B Stubbs, E Francis, F Gaughran… - Schizophrenia …, 2021 - Elsevier
As employment and relationship status are important long-term outcomes in individuals with
a diagnosis of first episode psychosis (FEP) disorders, there is a need to elucidate more …

What is the duration of untreated psychosis worldwide?–A meta-analysis of pooled mean and median time and regional trends and other correlates across 369 …

GS de Pablo, C Aymerich, D Guinart… - Psychological …, 2024 - cambridge.org
Duration of untreated psychosis (DUP) has been associated with poor mental health
outcomes. We aimed to meta-analytically estimate the mean and median DUP worldwide …